Sign up to save your podcasts
Or
Share HOPA '24, Site Agnositc T-DXd, & ALINA
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
HOPA '24, Site Agnositc T-DXd, & ALINA
What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma.
Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors.
Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this week's NEJM.
View all episodes
By John Bossaer
4.9
185185 ratings
What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma.
Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors.
Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this week's NEJM.
More shows like OncoPharm
View all
JAMA Clinical Reviews
504 Listeners
The Daily
113,129 Listeners
Up First from NPR
56,865 Listeners
Armchair Expert with Dax Shepard
69,607 Listeners
ASCO Guidelines
48 Listeners
The Peter Attia Drive
8,090 Listeners
OncLive® On Air
23 Listeners
Raising Good Humans
1,895 Listeners
Oncology Today with Dr Neil Love
61 Listeners
Huberman Lab
29,297 Listeners
The Money with Katie Show
1,547 Listeners
Two Onc Docs
197 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
46 Listeners
WolverHeme Happy Hour
30 Listeners
Good Hang with Amy Poehler
12,983 Listeners